This is a preview of subscription content, access via your institution
Access options
Data availability
Details about the data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology. 2016;55:291–300.
Zhao L-P, Boy M, Azoulay C, Clappier E, Sébert M, Amable L, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021;35:2720–4.
Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383:2628–38.
Zhao L-P, Schell B, Sébert M, Kim R, Lemaire P, Boy M, et al. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. Leukemia. 2021;35:2731–3.
Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021;137:3591–4.
Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189:1016–27.
Fraison J-B, Mekinian A, Grignano E, Kahn J-E, Arlet J-B, Decaux O, et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016;43:13–17.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.
Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol. 2013;88:130–4.
Comont T, Heiblig M, Rivière E, Terriou L, Rossignol J, Bouscary D, et al. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022;196:969–74.
Raaijmakers MHGP, Hermans M, Aalbers A, Rijken M, Dalm VASH, van Daele P, et al. Azacytidine treatment for VEXAS syndrome. Hemasphere. 2021;5:e661.
Ricard L, Hirsch P, Largeaud L, Deswarte C, Jachiet V, Mohty M, et al. Clonal haematopoiesis is increased in early onset in systemic sclerosis. Rheumatology. 2020;59:3499–504.
Hecker JS, Hartmann L, Rivière J, Buck MC, van der Garde M, Rothenberg-Thurley M, et al. CHIP & HIPs: clonal hematopoiesis is common in hip arthroplasty patients and associates with autoimmune disease. Blood. 2021;138:1727–32.
Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147–52.
Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, Seidl T, Abellan PP, et al. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica. 2013;98:1196–205.
Acknowledgements
We thank the French consortium MINHEMON, GFM, and French VEXAS groups.
Author information
Authors and Affiliations
Contributions
A Mekinian, PF, and LPZ designed the study and wrote the manuscript. FC and KL collected the data. SC and KD performed the analysis. A Mekinian, LPZ, LP, TC, A Maria, PP, LT, MAP, M-PG, NV, OBR, VG, HB, SD-Z, AB, SW, BDR, ED, SN-A, LV, VJ, CH, ST, JMTD, LF, EG, GD, PH, OK, LA, OF, and PF took care of the patients. All the authors critically reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
A Mekinian is an investigator of Celgene, Roche, Chugai founded trials with APHP and Hôpital 15–20 promotion; and received several fees for advisory boards from LFB, Sanofi, Shire, and Celgene. The other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mekinian, A., Zhao, L.P., Chevret, S. et al. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia 36, 2739–2742 (2022). https://doi.org/10.1038/s41375-022-01698-8
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41375-022-01698-8
This article is cited by
-
In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome
Nature Communications (2025)
-
VEXAS-Syndrom
Zeitschrift für Rheumatologie (2025)
-
Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis
Annals of Hematology (2025)
-
VEXAS syndrome
International Journal of Hematology (2025)
-
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management
Annals of Hematology (2025)
